A Multicenter Randomized Bioequivalence Study of a Novel Ready-to-Use Temozolomide Oral Suspension vs. Temozolomide Capsules

A Multicenter Randomized Bioequivalence Study of a Novel Ready-to-Use Temozolomide Oral Suspension vs. Temozolomide Capsules

Background: Temozolomide (TMZ) oral suspension (Ped-TMZ, KIZFIZO<sup>®</sup>) is being developed for the treatment of relapsed or refractory neuroblastoma, a rare cancer affecting infants and young children. The study assessed the safety and the bioequivalence of this novel pediatric for...

Full description

Bibliographic Details
Main Authors: François Ducray, Carole Ramirez, Marie Robert, Maxime Fontanilles, Charlotte Bronnimann, Olivier Chinot, Florian Estrade, Xavier Durando, Stéphanie Cartalat, Jeremy Bastid, Hugues Bienayme, Caroline Lemarchand
Format: Article
Language:English
Published: MDPI AG 2023-11-01
Series:Pharmaceutics
Subjects:
temozolomide
oral suspension
bioequivalence
pediatric formulation
Online Access:https://www.mdpi.com/1999-4923/15/12/2664

Similar Items

Similar Items